Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 226 - 250 of 325 in total

Haloxazolam

Experimental
Illicit

5-Bromo-2'-deoxyuridine 5'-(dihydrogen phosphate)

Experimental

R048-8071

Experimental

Bromo-Willardiine

Experimental

Bromo-WR99210

Experimental

5-Bromoindirubin

Experimental

Crolibulin

Crolibulin has been used in trials studying the treatment of Solid Tumor and Anaplastic Thyroid Cancer.
Investigational

Brivudine monophosphate

Experimental

PH-797804

PH-797804 has been investigated for the treatment of Osteoarthritis.
Investigational

IDD594

Experimental

RRx-001

RRx-001 has been used in trials studying the treatment of Lymphomas, Brain Metastases, Cholangiocarcinoma, Colorectal Neoplasms, and Malignant Solid Tumor, among others.
Investigational

4-CHLORO-3',3''-DIBROMOPHENOL-1,8-NAPHTHALEIN

Experimental

(6-[4-(AMINOMETHYL)-2,6-DIMETHYLPHENOXY]-2-{[4-(AMINOMETHYL)PHENYL]AMINO}-5-BROMOPYRIMIDIN-4-YL)METHANOL

Experimental

N-(3,5-dibromo-4-hydroxyphenyl)-4-hydroxy-3,5-dimethylbenzamide

Experimental

(2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE

Experimental

3-[6-bromo-2-fluoro-3-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-chlorobenzonitrile

Experimental

Brotizolam

Brotizolam is a sedative-hypnotic thienodiazepine drug which is a benzodiazepine analog. It demonstrates anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant effects. Brotizolam has similar effects to short-acting benzodiazepines such as triazolam. Brotizolam is indicated for 2-4 weeks of treatment for severe or debilitating insomnia. Brotizolam is an extremely potent...
Investigational
Withdrawn

Ertiprotafib

Ertiprotafib belongs to a novel class of insulin sensitizers developed for treatment of type 2 diabetes. In insulin-resistant rodent models, ertiprotafib and a close analog lowered both fasting blood glucose and insulin levels and improved glycemic excursion during an oral glucose tolerance test.
Investigational

3',5'-DIBROMO-2',4,4',6'-TETRAHYDROXY AURONE

Experimental

H-89

Experimental

6-(5-BROMO-2-HYDROXYPHENYL)-2-OXO-4-PHENYL-1,2-DIHYDROPYRIDINE-3-CARBONITRILE

Experimental

3-Bromo-7-Nitroindazole

Experimental

Ranirestat

Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels. It has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy.
Investigational

1-(5-BROMO-PYRIDIN-2-YL)-3-[2-(6-FLUORO-2-HYDROXY-3-PROPIONYL-PHENYL)-CYCLOPROPYL]-UREA

Experimental

(2S)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol

Experimental
Displaying drugs 226 - 250 of 325 in total